Provention Bio, a Sanofi Company

Clinical trials sponsored by Provention Bio, a Sanofi Company, explained in plain language.

Now part of Sanofi S.A. SNY NASDAQ

Biotech focused on preventing and treating autoimmune diseases, now part of Sanofi.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Teplizumab safety tracked for over 3 years in young diabetes patients Results expected Nov 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1 Completed 1 Terminated 1

New hope for celiac sufferers: drug targets stubborn symptoms

Symptom relief Completed

This study tested a drug called PRV-015 in 388 adults with celiac disease who still had symptoms like belly pain and bloating even after following a strict gluten-free diet. The goal was to see if the drug could reduce these symptoms better than a placebo. Participants took the d…

Phase 2 • Sponsor: Provention Bio, a Sanofi Company • Aim: Symptom relief

Last updated Jun 27, 2026 07:55 UTC

Provention Bio, a Sanofi Company

Upcoming readouts

New hope for celiac sufferers: drug targets stubborn symptoms